Renowned Neuro-Oncologist Will Work with Company to Develop Protocols for the Treatment of Brain Tumors
DENVER, CO / ACCESSWIRE / October 10, 2017 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today announced that Dr. Santosh Kesari has joined the Company's Advisory Board. Ranked among the top 1% of neuro-oncologists and neurologists in the nation, Dr. Kesari will work with the Company to develop clinical trial protocols to study the effects of Prana on cancers.
Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He is a board-certified neurologist and neuro-oncologist and is currently Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups. In addition, he is a member of the Los Angeles Biomedical Research Institute.
Earnest Blackmon, Chief Executive Officer of United Cannabis, commented on the announcement, "Dr. Kesari is an internationally recognized scientist and clinician, and we are honored that he has agreed to share his knowledge and expertise to help us advance our clinical programs focused on cancer care and brain health."
Commenting on the appointment, Dr. Kesari added, "There is a growing body of pre-clinical evidence that drugs developed from natural products can have a profound impact on tumor cell behavior and improving overall survival in a number of cancer subtypes. Similarly, plant-based therapeutics can play a role in supporting brain health and repair. United Cannabis' research program in these two areas is unique and has the potential to make an impact in both of these areas. I am looking forward to working with their research team and providing help as these programs move into the clinic."
About United Cannabis Corporation
United Cannabis is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. Our products include supplements, medical cannabis therapeutics and pharmaceutical drugs.
For further information, please visit www.unitedcannabis.us.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE: United Cannabis Corporation